Prostacyclin (PGI2), and prostaglandins D2 and E1, all inhibit aggregation of human platelets by stimulating adenylate cyclase. in platelets prelabelled with l4C adenine, PGI2 has a higher intrinsic activity than either PGD2 or PGE1, as well as a higher apparent affinity. PGE1 but not PGD2, inhibits the action of high concentrations of PGI2, both when added simultaneously with PGI2 and when added 3 min later. in the latter case the slow spontaneous fall in intracellular cyclic AMP is accelerated by PGE. but not by PGD2. PGF1α, at concentrations up to 100 μM neither stimulated the cyclase 1 by itself, nor did it inhibit the effects of PGI2, PGE1, or PGD2. PGF2α, which did cause a small increase in cyclic AMP, inhibited PGD2 strongly, PGE1 not at all, and PGI2 slightly at high concentrations. N0164, an inhibitor of aggregation induced by bis-enoic prostaglandins, inhibited cyclase stimulation by PGD2 but not by PGE1, PGE2, PGD1 or PGI2, though it reduced PGI2-induced inhibition of platelet aggregation. Preaddition of PGE1, but not of PGI2 or PGD2, at submaximal concentrations, inhibited subsequent response to high dose PGI2. The results suggest that PGE1 and PGD2 probably act on the same enzyme, but through a different receptor. PGE1 acts as a partial agonist for the receptor for PGI2, but in addition causes a tachyphylaxis not seen with PGI2 or with PGD2.